NEW YORK — Sorrento Therapeutics said on Tuesday that it has agreed to work with Mexico's National Institute of Genomic Medicine, or INMEGEN, on the development of a range of diagnostics and therapeutics for COVID-19 for the Mexican market.
Sorrento said that its Mexican subsidiary has signed a memorandum of understanding with INMEGEN to collaborate on the products, which include Sorrento's Covitrack SARS-CoV-2 antibody test for vaccinated individuals, neutralizing antibodies against the virus for use in outpatient and newly diagnosed COVID-19 patients, an antibody treatment for acute respiratory distress in hospitalized COVID-19 patients, and mRNA-based vaccines for various SARS-CoV-2 variants of concern.
Sorrento, which recently received Emergency Use Authorization from Mexican regulators for its Covi-Stix rapid SARS-CoV-2 antigen test, said that it plans to establish a research lab within INMEGEN's Mexico City-based facilities to support the alliance.
Additional terms were not disclosed.
"We are excited about our close collaboration with INMEGEN and intend to have Sorrento Mexico as a gateway to all Latin American countries for our innovative COVID diagnostic, vaccine, and therapeutic product candidates," Henry Ji, Sorrento's chairman and CEO, said in a statement.
About a year ago, San Diego-based Sorrento licensed a rapid point-of-care test that detects SARS-CoV-2 RNA from Columbia University.